Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 125.67

+0.4%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Wildbiftek	4/10/2020 8:53:26 PM
	of 961

NEJM article is out with inconclusive but very hopeful results for remdesivir: nejm.org The changes GILD made to some of their other trials were the subject of negative speculation in the days prior, but they appear to be in line with the protocol described in and the conclusions of this paper. That mortality for invasively intubated patients is only 18% compared to > 50% as reported elsewhere is definitely hopeful: npr.org It's still inconclusive as we don't have a well controlled comparison group. However it's notable that at baseline, the patients in this study were sicker than in other reported, worse outcomes so in theory that should work in favor of the drug. I think the FDA moves to conditionally approve with full approval contingent on the results of a large confirmatory RCT trial.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next